Maynard N D, Bihari D J, Dalton R N, Beale R, Smithies M N, Mason R C
Department of Surgery, Guy's Hospital, London, United Kingdom.
Chest. 1997 Jan;111(1):180-7. doi: 10.1378/chest.111.1.180.
To investigate the concept that splanchnic ischemia leads to hepatic dysfunction in the critically ill.
Prospective study and analysis of patient data.
A general ICU in an inner-city London teaching hospital.
Twenty-seven consecutive critically ill patients with evidence of inadequate tissue perfusion requiring pulmonary artery catheterization and mechanical ventilation.
In all patients, we measured the hepatic metabolism of lidocaine (lignocaine) to monoethylglycinexylidide (MEGX) and the clearance of indocyanine green (both dynamic, flow-dependent tests of hepatic function) over the first 3 days following admission to the ICU. These were compared with results of standard liver function tests and related to tonometric assessment of gastric intramucosal pH (pHim) and outcome.
There were no significant differences in bilirubin, aspartate aminotransferase, alkaline phosphatase, and prothrombin levels, or in indocyanine green clearance between survivors and nonsurvivors. On day 3, the median MEGX level was higher in survivors than in nonsurvivors (16 vs 2.4 ng/mL, p < 0.001), and the median MEGX level in nonsurvivors fell over the 3 days (20.6 to 2.4 ng/mL, p < 0.002). MEGX levels were significantly correlated with pHim (Spearman rank correlation coefficient [Rs] = 0.69, p < 0.001) as were the changes in the two measurements over the 3 days (Rs = 0.46, p < 0.02). The MEGX formation test and gastric pHim were the most discriminatory with regard to death and survival.
Our findings suggest that critically ill patients develop significant hepatic dysfunction that is associated with a poor outcome. This is likely to be due to a mismatch between hepatic metabolic demand and blood flow, and the MEGX formation test appears to be an extremely effective means of assessing liver function and flow in this group of patients.
探讨内脏缺血导致危重症患者肝功能障碍这一概念。
前瞻性研究及患者数据分析。
伦敦市中心一家教学医院的综合重症监护病房。
27例连续的危重症患者,有组织灌注不足的证据,需要进行肺动脉导管插入术及机械通气。
在所有患者中,我们在入住重症监护病房后的头3天测量了利多卡因(昔罗卡因)向单乙基甘氨酰二甲苯酰胺(MEGX)的肝脏代谢以及吲哚菁绿的清除率(两者均为肝功能的动态、血流依赖性检测)。将这些结果与标准肝功能测试结果进行比较,并与胃黏膜内pH值(pHim)的张力测定评估及预后相关联。
幸存者与非幸存者在胆红素、天冬氨酸转氨酶、碱性磷酸酶和凝血酶原水平或吲哚菁绿清除率方面无显著差异。在第3天,幸存者的MEGX水平中位数高于非幸存者(16对2.4 ng/mL,p<0.001),非幸存者的MEGX水平中位数在3天内下降(20.6至2.4 ng/mL,p<0.002)。MEGX水平与pHim显著相关(斯皮尔曼等级相关系数[Rs]=0.69,p<0.001),3天内这两项测量值的变化也显著相关(Rs=0.46,p<0.02)。MEGX生成试验和胃pHim对死亡和存活的鉴别能力最强。
我们的研究结果表明,危重症患者会出现明显的肝功能障碍,且与不良预后相关。这可能是由于肝脏代谢需求与血流不匹配所致,MEGX生成试验似乎是评估该组患者肝功能和血流的极其有效的方法。